Clinical Trial

A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple doses of ABBV-313 in healthy adult participants.
Trial Details
NCT Number NCT07673120
Lead Sponsor AbbVie
Conditions Healthy Volunteers
Enrollment 64 participants
Start Date 2026-06-22
Primary Completion 2028-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-06-29